Medpace Holdings, Inc. $MEDP Shares Sold by Empirical Finance LLC

Empirical Finance LLC decreased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 14.9% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 10,782 shares of the company’s stock after selling 1,881 shares during the period. Empirical Finance LLC’s holdings in Medpace were worth $5,710,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. California State Teachers Retirement System increased its stake in Medpace by 53,619.6% in the second quarter. California State Teachers Retirement System now owns 13,989,649 shares of the company’s stock valued at $7,408,778,000 after purchasing an additional 13,963,607 shares during the last quarter. BlackRock Inc. acquired a new position in shares of Medpace during the 2nd quarter valued at about $1,323,047,000. AQR Capital Management LLC increased its stake in shares of Medpace by 31.6% during the 4th quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock valued at $758,061,000 after acquiring an additional 324,293 shares during the last quarter. Wasatch Advisors LP lifted its holdings in shares of Medpace by 14.0% during the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after acquiring an additional 116,354 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of Medpace by 3.8% during the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock worth $374,836,000 after acquiring an additional 24,625 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Brian T. Carley sold 5,000 shares of Medpace stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the sale, the director owned 27,825 shares in the company, valued at $16,935,129.75. This trade represents a 15.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Robert O. Kraft sold 3,858 shares of the business’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $617.81, for a total transaction of $2,383,510.98. Following the transaction, the director directly owned 955 shares in the company, valued at approximately $590,008.55. The trade was a 80.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 134,471 shares of company stock valued at $82,151,311. Corporate insiders own 20.50% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Jefferies Financial Group downgraded shares of Medpace from a “buy” rating to a “hold” rating and increased their price target for the stock from $490.00 to $515.00 in a research note on Tuesday, July 7th. Leerink Partners set a $620.00 price objective on Medpace in a report on Thursday, July 23rd. Mizuho increased their target price on Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Barclays set a $600.00 price target on Medpace in a research report on Thursday, July 23rd. Finally, Weiss Ratings upgraded Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 12th. Three equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $595.20.

Medpace Stock Down 0.1%

Shares of Medpace stock traded down $0.40 during trading hours on Tuesday, hitting $590.89. The company’s stock had a trading volume of 185,216 shares, compared to its average volume of 338,222. The business has a fifty day moving average of $575.80 and a 200 day moving average of $501.17. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90. The company has a market capitalization of $16.49 billion, a PE ratio of 34.64, a P/E/G ratio of 2.64 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. During the same period in the prior year, the company earned $3.10 EPS. The firm’s revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, sell-side analysts anticipate that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.